Kunath F, et al. - In castration-sensitive/-resistant prostate cancer, researchers evaluated the time of initiation of androgen deprivation therapy (ADT) monotherapy and combined treatments. Cochrane reviews, systematic reviews, and randomized controlled trials, phase III and ongoing trials, and screened the of interest were used for this narrative review. They categorized the recognized references by medication (standard ADT, androgen biosynthesis inhibitor, androgen receptor antagonists or combined therapies) and tumor stage (castration sensitive or resistant). They suggested a decrease in symptoms of disease progression prolonged progression-free and overall survival with early standard ADT. They found an increase in the combination of early standard ADT with new antihormonal drugs in castration-sensitive metastatic prostate cancer to gain further survival and quality of life benefits.